reports
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule ...
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to purchase an aggregate of 320,000 shares of common stock to one newly hired employee as an inducement material to such employee’s acceptance of employment with Geron. The stock options have an exercise price of $1.34 per share, which is equal to the closing price of Geron’s common stock on the grant ...
MediciNova Announces Completion of Patient Enrollment Evaluating MN-16...
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This...
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
VRDN VIRIDIAN THERAPEUTICS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
GLUE MONTE ROSA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SGMT SAGIMET BIOSCIENCES INC
ORKA ORUKA THERAPEUTICS INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
ACRS ACLARIS THERAPEUTICS INC.
WVE WAVE LIFE SCIENCES
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
VRDN VIRIDIAN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Wedbush Research
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
FMCC FEDERAL HOME LOAN MORTGAGE CORPORATION
STOK STOKE THERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
NATL NCR ATLEOS CORPORATION
DBD DIEBOLD NIXDORF INCORPORATED
- Laura Chico
- Thomas Yip
Geron Corporation Announces Strategic Restructuring Plan to Position t...
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholder...
- Wedbush Research
SRPT SAREPTA THERAPEUTICS INC.
KURA KURA ONCOLOGY INC.
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
AMZN AMAZON.COM INC.
ARVN ARVINAS HOLDING
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DASH DOORDASH
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
CGEM CULLINAN ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
PRME PRIME MEDICINE INC
CART MAPLEBEAR INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relat...
Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in lower-risk MDS Long-term follow-up analysis from IMerge supports favorable survival trends and durable clinical benefit in LR-MDS Additional analyses in myelofibrosis an...
MediciNova Announces Update and Basic Characteristic Randomized Patien...
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the patients’ basic characteristics data from its Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock. The options and RSUs were granted as of December 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were grant...
BioCryst Receives Early Termination of HSR Waiting Period for Astria A...
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to BioCryst’s proposed acquisition of Astria Therapeutics, Inc. (the “Merger”). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quart...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Message from the CEO to MediciNova Shareholders
Message from the CEO to MediciNova Shareholders Strengthening MN-001’s Scientific Foundation and Clinical Outlook LA JOLLA, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dear Fellow Shareholders, Following the recent publication in the Journal of Atherosclerosis and Thrombosis, I would like to provide additional perspective on why this research represents a significant milestone for MediciNova and our MN-001 program. The study, conducted in collaboration with a leading Japanese academic research team, revealed a novel mechanism by MN-002, the primary metabolite of MN-001, enhances choles...
- Wedbush Research
SHOP SHOPIFY INC.
TRIP TRIPADVISOR INC.
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
OVID OVID THERAPEUTICS
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
UBER UBER TECHNOLOGIES INC.
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
VRDN VIRIDIAN THERAPEUTICS INC
VOR VOR BIOPHARMA
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
ATXS ASTRIA THERAPEUTICS INC
YOU CLEAR SECURE INC
SLDB SOLID BIOSCIENCES INC
JBIO JADE BIOSCIENCES INC
IMA IMAGENEBIO INC.
KLAR KLARNA GROUP PLC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Laura Chico
- Thomas Yip
- Wedbush Research
- Laura Chico
- Thomas Yip
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Re...
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor LA JOLLA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), is pleased to announce the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s Drug Development programs and will lead the Scientific Advisory Board upon its formation. Dr. Christopher D. Brede...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.